CUTTING EDGE THERAPIES
Novel Colitis and Crohn’s Treatment Uses Cholera Toxin to Deliver IL-10
Scientists fused IL-10 to a component of cholera toxin to enable the local administration of the drug while avoiding systemic toxicities.
- Advertisement -
Allergy & Asthma
KIT Inhibitor CDX-0159 Shows Potential As Therapy for Mast Cell Diseases
Celldex Therapeutics' CDX-0159, an inhibitor of the KIT receptor, led to sustained reductions in plasma tryptase levels in the phase 1 trial.
Dupilumab for Eosinophilic Esophagitis: “Pivotal Data” in Phase 3 Trial
Dupixent (dupilumab), developed by Regeneron and Sanofi, has shown “significant efficacy” for Eosinophilic Esophagitis in a phase 3 trial.
Eczema Treatment in Adults: Latest Research and Medications
Everything that you should know about the treatment of eczema in adults, including the latest research, medications, and recommendations.
Infectious Diseases
BTK Inhibitor Acalabrutinib Supports Patients with Severe Cases of COVID-19
Calquence (Acalabrutinib), Astrazeneca's bruton tyrosine kinase inhibitor, is thought to treat COVID-19 by suppressing lung macrophages.
Altimmune To Initiate Phase 1/2 Clinical Trial of COVID-19 Therapy T-COVID
T-COVID is anticipated to provide clinical benefit to COVID-19 patients that are not yet hospitalized in the phase 1/2 clinical trial.
Novavax Expands Manufacturing Capacity by Acquiring Praha Vaccines
Novavax has purchased Praha Vaccines, a biologics manufacturer in the Czech Republic, to support mass production of its COVID-19 vaccine.
Autoimmune Disease
Novel Colitis and Crohn’s Treatment Uses Cholera Toxin to Deliver IL-10
Scientists fused IL-10 to a component of cholera toxin to enable the local administration of the drug while avoiding systemic toxicities.
T-Cell miRNA Profile Distinguishes IBD and Predicts Treatment Escalation
The microRNA expression profile in T-cells was found to distinguish IBD patients and predict the need for treatment escalation.
Implications of the Lung Microbiota for GI Disease and Human Health
Healthy lungs, initially thought to be free from bacteria, are now known to host a microbiota that communicates with various body sites.
Neurological Disorders
Researchers Profile Immune Cells Implicated in Neurodegenerative Diseases
The team of Dr. Katerina Akassoglou at Gladstone Institutes and UCSF studied the gene signature of pathogenic innate immune cells in the CNS.
Seneca Biopharma: Phase 3 Trial of Stem Cell Therapy NSI-566 for ALS
Seneca Biopharma is working with the FDA to finalize the design of a phase 3 trial of neural stem cell NSI-566 for the treatment of ALS.
Alterations in the Gut Microbiome May Contribute to Autism Spectrum Disorder Pathogenesis
By contributing to changes in metabolism, immunity, and neurophysiology, alterations in the gut microbiome influence developmental processes in the brain and are potentially involved in Autism Spectrum Disorder pathogenesis.
Cancer
Exosome-Based Imaging-Guided Cancer Therapy Activates Immune Cells
Tumor-derived exosomes loaded with the photosensitizing pigment chlorin e6 permitted targeted chemotherapy and stimulated the immune system.
Minimally Invasive Blood Test Can Detect Cancer Years Prior to Diagnosis
Chinese scientists showed that a blood test for circulating tumor DNA methylation profiles could detect cancer years prior to diagnosis.
Lipid-Laden Neutrophils Foster Breast Cancer Metastases in the Lungs
Jackson Laboratory researchers have found that lipid accumulation by neutrophils supports metastatic breast cancer development in the lungs.
Transplantation
NuVasive Publication: Efficacy of Synthetic Putty in Lumbar Fusion
NuVasive, Inc. (Nasdaq: NUVA) has announced a recent publication demonstrating the efficacy of their synthetic bioactive putty in lumbar fusion.
Limited Efficacy of Immunosuppressive Strategy in Transplant Patients Associated with Immunoproteosome
The limited efficacy of a proteosome inhibitor-based immunosuppressive strategy in highly HLA-sensitized transplant recipients has been associated with the immunoproteosome.
Photopheresis Found to Treat GvHD By Favorably Altering WBC Profile
Extracorporeal photophersis was found to treat steroid-resistant GvHD by favorably altering a population of circulating white blood cells.